<DOC>
	<DOCNO>NCT02817789</DOCNO>
	<brief_summary>Transcatheter Aortic Valve Implantation ( TAVI ) method choice treat aortic stenosis old frail patient . Antiplatelet therapy must associate procedure week implantation aim minimize cerebral embolization . But , best antiplatelet regimen determine . In context , investigator want evaluate safety use ticagrelor alone versus standardized therapy involve lysine acetylsalicylate clopidogrel . In study , randomly compare 154 patient group term early safety ( 30 day ) procedure .</brief_summary>
	<brief_title>Safety Profile Evaluation TICagrelor Alone Compared Combination Lysine Acetylsalicylate-Clopidogrel Context Transcatheter Aortic Valve Implantation ( TAVI )</brief_title>
	<detailed_description>In spite use combination lysine acetylsalicylate clopidogrel procedure TAVI , rate stroke remain high , 4 10 % regard study registry . None therapeutic regulatory authorisation indication . On hand , rate bleed event also high old frail population . That , consider pharmacological specificity , investigator hypothesize ticagrelor , use alone , could non-inferior safety criterion combination lysine acetylsalicylate clopidogrel . Our study want evaluate safety profile Ticagrelor alone ( 180 mg load dose intervention 90 mg twice daily 30 day procedure ) compare standardized treatment combine lysine acetylsalicylate ( 75 mg 75 mg daily procedure ) clopidogrel ( 300mg load dose 75 mg daily procedure ) . Patients follow one month . Then place usual antiplatelet treatment ( clopidogrel lysine acetylsalicylate two additional month lysine acetylsalicylate alone lifelong ) .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Acetylsalicylic acid lysinate</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Female male age &gt; 18 year Patient eligible TAVI recommend French health care system authority ( HAS ) Allergy , hypersensitivity , contraindication lysine acetylsalicylate , clopidogrel , ticagrelor , anticoagulation magnetic resonance imaging ( MRI ) CTscanner contrast agent Use Cytochrome P3a ( CYP3a ) inhibitor Need chronic anticoagulation Previous percutaneous coronary intervention acute coronary syndrome require dual antiplatelet therapy Previous cardiac surgery valve replacement Prior stroke , transient ischemic attack ( TIA ) know carotid stenosis &gt; 70 % Active pathological bleeding gastric ulcer &lt; 3month Known thrombocytopenia , anemia coagulopathy Severe kidney hepatic impairment Hemodynamic instability Refusal Transfusion Significant mental impairment Inability give inform consent comply study related procedure high likelihood unavailable followup Pregnant breastfeed woman Women childbearing potential without effective contraception ( oestroprogestative , intrauterine device ) Participant another investigational drug device study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>TAVI</keyword>
	<keyword>Antiplatelet agent</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Cerebrovascular event</keyword>
</DOC>